Unexpectedly catapulted into global fame as a COVID-19 vaccine maker, BioNTech is on the verge of returning to its oncology ...
The developer of the former Pfizer building in Midtown said the building was never at risk of collapse and the repairs are ...
Among healthy adults receiving the JN.1- or KP.2-adapted mRNA seasonal COVID-19 vaccine, neutralizing antibody responses were similar.
The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...
Moderna Inc. Chief Executive Officer Stephane Bancel said he sees the pending launch of a planned flu vaccine as a chance to start a public conversation about how mRNA technology can offer better ...
On June 16, 2026, U.S. District Judge Gregory B. Williams of the United States District Court for the District of Delaware issued a memorandum order resolving three partial motions to dismiss ...
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
While the document circulating is authentic, it is not a list of side effects of Pfizer's mRNA vaccine against COVID-19. It is a list of adverse events of special interest. Adverse events are unwanted ...
BioNTech BNTX0.93%increase; up pointing triangle plans to shrink its workforce and manufacturing network, as the German biotech company seeks to cut costs and downsize its footprint after demand for ...
LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results